<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background and aims: To investigate the expression of Egfl7 in <z:mpath ids='MPATH_458'>normal</z:mpath> adult human tissues and human <z:e sem="disease" ids="C0205853" disease_type="Neoplastic Process" abbrv="">epithelial tumors</z:e>. Methods: RT-PCR and Western blot were employed to detect Egfl7 expression in <z:mpath ids='MPATH_458'>normal</z:mpath> adult human tissues and 10 human <z:e sem="disease" ids="C0205853" disease_type="Neoplastic Process" abbrv="">epithelial tumors</z:e> including <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> (<z:mp ids='MP_0003331'>HCC</z:mp>), <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, <z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, malignant <z:hpo ids='HP_0009733'>glioma</z:hpo>, <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> and <z:e sem="disease" ids="C0740457" disease_type="Neoplastic Process" abbrv="">renal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Immunohistochemistry and cytoimmunofluorescence were subsequently used to determine the localization of Egfl7 in human <z:e sem="disease" ids="C0205853" disease_type="Neoplastic Process" abbrv="">epithelial tumor</z:e> tissues and cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>ELISA was also carried out to examine the serum Egfl7 levels in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, correlations between Egfl7 expression and clinicopathological features as well as prognosis of <z:mp ids='MP_0003331'>HCC</z:mp> and <z:hpo ids='HP_0003002'>breast cancer</z:hpo> were also analyzed on the basis of immunohistochemistry results. Results: Egfl7 was differentially expressed in 19 adult human <z:mpath ids='MPATH_458'>normal</z:mpath> tissues and was overexpressed in <z:hpo ids='HP_0000001'>all</z:hpo> 10 human <z:e sem="disease" ids="C0205853" disease_type="Neoplastic Process" abbrv="">epithelial tumor</z:e> tissues </plain></SENT>
<SENT sid="4" pm="."><plain>The serum Egfl7 level was also significantly elevated in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>The increased Egfl7 expression in <z:mp ids='MP_0003331'>HCC</z:mp> correlated with vein invasion, absence of capsule formation, multiple <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> nodes and poor prognosis </plain></SENT>
<SENT sid="6" pm="."><plain>Similarly, upregulation of Egfl7 in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> correlated strongly with TNM stage, <z:e sem="disease" ids="C0024232" disease_type="Neoplastic Process" abbrv="">lymphatic metastasis</z:e>, <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptor positivity, Her2 positivity and poor prognosis.  Conclusions: Egfl7 is significantly upregulated in human <z:e sem="disease" ids="C0205853" disease_type="Neoplastic Process" abbrv="">epithelial tumor</z:e> tissues, suggesting Egfl7 to be a potential biomarker for human <z:e sem="disease" ids="C0205853" disease_type="Neoplastic Process" abbrv="">epithelial tumors</z:e>, especially <z:mp ids='MP_0003331'>HCC</z:mp> and <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
</text></document>